View Older Stories View More Recent Stories
-
Stelexis Therapeutics Closes $43 million Series A to Expand Novel Platform Focused on Cancer Interception
-
Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer
-
Cabaletta Bio Closes $50 Million Series B Financing to Establish Translational Research and Advanced Manufacturing Capabilities for Chimeric AutoAntibody Receptor (CAAR) T Cell Products to Treat B Cel
-
Cabaletta Bio Closes $50 Million Series B Financing to Establish Translational Research and Advanced Manufacturing Capabilities for Chimeric AutoAntibody Receptor (CAAR) T Cell Products to Treat B Cel
-
Axovant Announces Presentation at J.P. Morgan Healthcare Conference and Anticipated 2019 Clinical Development Milestones
-
Nuvo Pharmaceuticals™ to Host Conference Call/Audio Webcast to Discuss the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo® and other Related Assets
-
Nuvo Pharmaceuticals™ Announces Completion of the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo® and other Related Assets
-
ARS Pharmaceuticals Advances Clinical Program for Intranasal Epinephrine Spray
-
Nuvo Pharmaceuticals™ Declared Winning Bidder to Acquire Commercial Products from Aralez Pharmaceuticals
-
Aralez Pharmaceuticals to Seek Court Approval of Previously Announced "Stalking Horse" Transactions for Substantially All Assets
-
Oncorus Announces Nomination of ONCR-177, A Next-Generation Oncolytic Virus Therapy Clinical Candidate for Multiple Solid Tumor Indications
-
SHINE And Deerfield Close $150 Million Financing Commitment To Support Diagnostic And Therapeutic Medical Isotope Manufacturing
-
Form 13F-HR DEERFIELD MANAGEMENT For: Sep 30
-
Citco Launches New SaaS Æxeo Treasury™ Solution on Amazon Web Services
-
Dana-Farber Cancer Institute and Deerfield Collaborate to Create the Center for Protein Degradation
-
Citco Launches New SaaS Æxeo Treasury™ Solution on Amazon Web Services
-
Neos Therapeutics Reports Third Quarter 2018 Financial Results
-
InCarda Therapeutics Provides Corporate Update Highlighting Fundraising and Clinical Development Milestones
-
Nuvo Pharmaceuticals™ Announces 2018 Third Quarter Results
-
Mirum Pharmaceuticals Secures $120 Million in Series A Financing to Develop Phase 3-Ready Maralixibat for Rare Liver Diseases
-
NeoChord Announces $25 Million Series D Financing to Accelerate Development of Two Transcatheter Chordal Repair Programs
-
NeoChord Announces $25 Million Series D Financing to Accelerate Development of Two Transcatheter Chordal Repair Programs
-
UNC-Chapel Hill and Deerfield Management announce the creation of Pinnacle Hill to accelerate the discovery of new medicines
-
Deerfield Provides $125 million Debt Financing to Tris Pharma
-
Deerfield and Stan Rowe Create a Next Generation Therapeutic Device Incubator, NXT Biomedical
-
Nuvo Pharmaceuticals™ Announces Signing of Definitive Agreements to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals
-
Aralez Pharmaceuticals Enters Into Definitive "Stalking Horse" Purchase Agreements For Substantially All Assets
-
Ex-Deerfield partners get prison in case over U.S. agency leaks
-
Epic Sciences Announces Completion of $52 Million Series E Financing
-
Allogene Therapeutics Completes a $120 Million Private Financing
-
University of California San Diego and Deerfield Management Create Poseidon Innovation to Advance Disease-Curing Therapeutics
-
Alimera Sciences Announces Exchange of Series B Preferred Stock for Newly Issued Series C Preferred Stock
-
Nuvo Pharmaceuticals™ Announces Extension of Exclusivity Period with Aralez and Deerfield
-
Form 13F-HR DEERFIELD MANAGEMENT For: Jun 30
-
Orchard Therapeutics Announces $150 Million Series C Financing to Advance Gene Therapy Pipeline
-
Nuvo Pharmaceuticals™ Announces Letter of Intent to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals
-
Aralez Pharma (ARLZ) Announces Agreement to Sell Substantially All Assets to Nuvo Pharmaceuticals Inc. for $110M
-
Aralez Pharmaceuticals To Enter Into Purchase Agreements To Sell Substantially All Assets
-
Aerie Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
-
MedAvail Completes Financing Round, Adds Express Scripts as New Investor
-
Alector Announces $133 Million in Series E Financing to Advance Broad Portfolio of Immuno-Neurology and Immuno-Oncology Programs
-
Form 4 CONSTELLATION PHARMACEUT For: Jul 23 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Bridge Medicines Enters Agreement with Memorial Sloan Kettering to Develop Kidney-Specific Delivery Platform for the Treatment of Acute Kidney Injury
-
Aerie Pharmaceuticals Announces Deerfield’s Conversion of Convertible Notes into Aerie Common Stock and Establishment of an Undrawn $100M Credit Facility with Deerfield
-
Form 3 CONSTELLATION PHARMACEUT For: Jul 18 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Appello Completes $10.5 Million Series A Financing Led by Deerfield Management and Mountain Group Partners
-
Ablexis Targets Market Expansion Opportunities for AlivaMab Mouse Following Acquisition by Deerfield Management and the Founding of AlivaMab Discovery Services
-
Metacrine Completes $65 Million Series C Financing
-
Form 4 Kiniksa Pharmaceuticals, For: May 29 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Northwestern University and Deerfield Management launch Lakeside Discovery to provide tomorrow's solutions in healthcare

